- Home
- CHRS vs SNCR Comparison
CHRS vs SNCR Comparison
Compare CHRS & SNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SNCR
- Stock Information
- Founded
- CHRS 2010
- SNCR 2000
- Country
- CHRS United States
- SNCR United States
- Employees
- CHRS N/A
- SNCR N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SNCR EDP Services
- Sector
- CHRS Health Care
- SNCR Technology
- Exchange
- CHRS Nasdaq
- SNCR Nasdaq
- Market Cap
- CHRS 112.5M
- SNCR 79.3M
- IPO Year
- CHRS 2014
- SNCR 2006
- Fundamental
- Price
- CHRS $0.78
- SNCR $6.84
- Analyst Decision
- CHRS Buy
- SNCR Strong Buy
- Analyst Count
- CHRS 3
- SNCR 1
- Target Price
- CHRS $4.68
- SNCR $13.00
- AVG Volume (30 Days)
- CHRS 1.5M
- SNCR 108.6K
- Earning Date
- CHRS 05-12-2025
- SNCR 05-06-2025
- Dividend Yield
- CHRS N/A
- SNCR N/A
- EPS Growth
- CHRS N/A
- SNCR N/A
- EPS
- CHRS N/A
- SNCR N/A
- Revenue
- CHRS $272,251,000.00
- SNCR $172,842,000.00
- Revenue This Year
- CHRS N/A
- SNCR $1.99
- Revenue Next Year
- CHRS $19.78
- SNCR $5.51
- P/E Ratio
- CHRS $1.83
- SNCR N/A
- Revenue Growth
- CHRS 19.87
- SNCR 4.64
- 52 Week Low
- CHRS $0.66
- SNCR $6.31
- 52 Week High
- CHRS $2.43
- SNCR $15.46
- Technical
- Relative Strength Index (RSI)
- CHRS 40.90
- SNCR 35.19
- Support Level
- CHRS $0.74
- SNCR $6.31
- Resistance Level
- CHRS $0.82
- SNCR $7.28
- Average True Range (ATR)
- CHRS 0.07
- SNCR 0.49
- MACD
- CHRS -0.00
- SNCR 0.01
- Stochastic Oscillator
- CHRS 19.71
- SNCR 20.95
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About SNCR Synchronoss Technologies Inc.
Synchronoss Technologies Inc is a provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.